Top

Published in:

01-10-2017 | Review Article

Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy

Authors: Li Li, Ping Tang, Shun Li, Xiang Qin, Hong Yang, Chunhui Wu, Yiyao Liu

Published in: Medical Oncology | Issue 10/2017

Abstract

Notch signaling pathway is evolutionarily conserved in mammals, which plays an important role in cell development and differentiation. In recent years, increasing evidence has shown that aberrant activation of Notch is associated with tumor process. Aberrant activation of Notch signaling pathway has been found in many different solid tumors can induce cell proliferation, metastasis and epithelial-mesenchymal transition. Notch receptor and its ligand are both single transmembrane protein, and Notch is activated when it binds to the Notch ligand of neighbor cells. The signal transduction of Notch signaling pathway is only between cells that are in contact with each other, which is independent of second messengers. Thus, Notch needs to cross talk with other signaling pathways, including PI3K/AKT, NF-κB, integrin and miRNAs, to precisely regulate cell fate. In this review, we summarize the roles of Notch signaling pathway in tumor metastasis and its regulatory mechanisms and discuss the current treatment strategies targeting Notch signal pathway.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.CrossRefPubMed

Charpentier M, Martin S. Interplay of stem cell characteristics, EMT, and microtentacles in circulating breast tumor cells. Cancers. 2013;5(4):1545–65. doi:10.3390/cancers5041545.CrossRefPubMedPubMedCentral

Andersson M, Olsen JH. Malignant mesotheliomas in Denmark 1943–1980. Cancer statistics 9. Ugeskr Laeger. 1984;146(14):1085–7.PubMed

Zardawi SJ, Zardawi I, McNeil CM, Millar EK, McLeod D, Morey AL, et al. High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology. 2010;56(3):286–96. doi:10.1111/j.1365-2559.2009.03475.x.CrossRefPubMed

Danza G, Di Serio C, Ambrosio MR, Sturli N, Lonetto G, Rosati F, et al. Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int J Cancer. 2013;133(11):2577–86. doi:10.1002/ijc.28293.PubMedPubMedCentral

Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang C, et al. High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS ONE. 2012;7(4):e35022. doi:10.1371/journal.pone.0035022.CrossRefPubMedPubMedCentral

Yang Y, Ahn Y-H, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200—dependent pathway in mice. J Clin Investig. 2011;121(4):1373–85. doi:10.1172/jci42579.CrossRefPubMedPubMedCentral

Liu H, Wang J, Liu Z, Wang L, Liu S, Zhang Q. Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast. Medicine. 2017;96(16):e6663. doi:10.1097/MD.0000000000006663.CrossRefPubMedPubMedCentral

Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530–7. doi:10.1158/0008-5472.CAN-05-1069.CrossRefPubMed

10.

Chance O. Value of statistics in the study of cancer of the uterine cervix. Comptes rendus de la Societe francaise de gynecologie. 1951;21(7):305–11.PubMed

11.

Dotta JS, Delporte TV. Statistics on the treatment of prostatic cancer. Revista argentina de urologia. 1951;20(9–11):255–7.PubMed

12.

Mumm J. Notch signaling: from the outside in. Dev Biol. 2000;228(2):151–65. doi:10.1006/dbio.2000.9960.CrossRefPubMed

13.

Lai EC. Notch signaling: control of cell communication and cell fate. Development. 2004;131(5):965–73. doi:10.1242/dev.01074.CrossRefPubMed

14.

Cesarani F, Garbagnoli E. Local recurrence and lymphatic and osseous metastases following surgery of breast cancer; radiotherapy department statistics for 1944-50. Athena; rassegna mensile di biologia, clinica e terapia. 1951;17(7–8):189–92.PubMed

15.

Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216–33. doi:10.1016/j.cell.2009.03.045.CrossRefPubMedPubMedCentral

16.

Weinmaster G. Notch signal transduction a real rip and more. Curr Opin Genet Dev. 2000;10:363–9.CrossRefPubMed

17.

Nahum AM. Biting the bullet: minimum standards for reporting cancer treatment statistics. Head Neck Surg. 1979;1(3):201.CrossRefPubMed

18.

Upton AC. Survey: reporting practices for cancer treatment statistics. Head Neck Surg. 1979;1(6):500.CrossRef

19.

Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338–51. doi:10.1038/nrc3035.CrossRefPubMed

20.

Ellisen LW, Bird J, West PC, et al. TAN+1, the human hormolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastie neoplasms. Cell. 1991;66(4):649–61.CrossRefPubMed

21.

Weng AP, Ferrando AA, Lee W, Morris JP IV, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Thomas Look A, Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269–71. doi:10.1126/science.1102160.CrossRefPubMed

22.

Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Statnikov A, Guiu J, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18(3):268–81. doi:10.1016/j.ccr.2010.08.006.CrossRefPubMedPubMedCentral

23.

Wu F, Stutzman A, Mo YY. Notch signaling and its role in breast cancer. Front Biosci. 2007;12:4370–83.CrossRefPubMed

24.

Ma YC, Shi C, Zhang YN, Wang LG, Liu H, Jia HT, et al. The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells. PLoS ONE. 2012;7(3):e33414. doi:10.1371/journal.pone.0033414.CrossRefPubMedPubMedCentral

25.

Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008;27(44):5833–44. doi:10.1038/onc.2008.190.CrossRefPubMed

26.

Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X, Lu XH, et al. The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Cell Death Dis. 2013;4:e847. doi:10.1038/cddis.2013.375.CrossRefPubMedPubMedCentral

27.

Zhang Y, Li B, Ji ZZ, Zheng PS. Notch1 regulates the growth of human colon cancers. Cancer. 2010;116(22):5207–18. doi:10.1002/cncr.25449.CrossRefPubMed

28.

Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 2007;21(5):562–77. doi:10.1101/gad.1484707.CrossRefPubMedPubMedCentral

29.

Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011;208(10):1963–76. doi:10.1084/jem.20110198.CrossRefPubMedPubMedCentral

30.

Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M, et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate. 2008;68(1):50–60. doi:10.1002/pros.20650.CrossRefPubMed

31.

Konishi J, Yi F, Chen X, Vo H, Carbone DP, Dang TP. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene. 2010;29(4):589–96. doi:10.1038/onc.2009.366.CrossRefPubMed

32.

Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14(5):779–86.PubMed

33.

PRESENTATION of results in the treatment of cancer. V. World Health Organization Expert Committee on Health Statistics. Br J Radiol. 1951;24(282):311–314. doi:10.1259/0007-1285-24-282-311.

34.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64. doi:10.1126/science.1203543.CrossRefPubMed

35.

Li S, Zhang J, Yang H, Wu C, Dang X, Liu Y. Copper depletion inhibits CoCl2-induced aggressive phenotype of MCF-7 cells via downregulation of HIF-1 and inhibition of Snail/Twist-mediated epithelial-mesenchymal transition. Sci Rep. 2015;5:12410. doi:10.1038/srep12410.CrossRefPubMedPubMedCentral

36.

Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci. 2008;105(17):6392–7. doi:10.1073/pnas.0802047105.CrossRefPubMedPubMedCentral

37.

Kao SH, Wu KJ, Lee WH. Hypoxia, epithelial-mesenchymal transition, and TET-mediated epigenetic changes. J Clin Med. 2016;. doi:10.3390/jcm5020024.PubMedPubMedCentral

38.

Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, et al. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat. 2011;126(1):15–25. doi:10.1007/s10549-010-0883-2.CrossRefPubMed

39.

Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. 2012;113(5):1501–13. doi:10.1002/jcb.24019.PubMed

40.

Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222–6. doi:10.1038/nature04695.CrossRefPubMed

41.

Peinado H, Portillo F, Cano A. Switching on-off Snail: LOXL2 versus GSK3beta. Cell Cycle. 2005;4(12):1749–52. doi:10.4161/cc.4.12.2224.CrossRefPubMed

42.

Yuan XW, Wang DM, Hu Y, Tang YN, Shi WW, Guo XJ, et al. Hepatocyte nuclear factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibition of epithelial-mesenchymal transition. J Biol Chem. 2013;288(43):31206–16. doi:10.1074/jbc.M113.480285.CrossRefPubMedPubMedCentral

43.

Ramms L, Fabris G, Windoffer R, Schwarz N, Springer R, Zhou C, et al. Keratins as the main component for the mechanical integrity of keratinocytes. Proc Natl Acad Sci USA. 2013;110(46):18513–8. doi:10.1073/pnas.1313491110.CrossRefPubMedPubMedCentral

44.

Mierke CT. The fundamental role of mechanical properties in the progression of cancer disease and inflammation. Rep Prog Phys. 2014;77(7):076602. doi:10.1088/0034-4885/77/7/076602.CrossRefPubMed

45.

Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge SA. Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol. 2013;201(2):279–92. doi:10.1083/jcb.201209151.CrossRefPubMedPubMedCentral

46.

Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251(4996):936–9.CrossRefPubMed

47.

Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, et al. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol. 1995;128(5):929–38.CrossRefPubMed

48.

Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004;64(16):5720–7. doi:10.1158/0008-5472.CAN-04-0811.CrossRefPubMed

49.

Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 2009;15(2):RA32–40.PubMed

50.

Li L, Zhao F, Lu J, Li T, Yang H, Wu C, et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappaB activation. PLoS ONE. 2014;9(4):e95912. doi:10.1371/journal.pone.0095912.CrossRefPubMedPubMedCentral

51.

Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5(3):483–93. doi:10.1158/1535-7163.MCT-05-0299.CrossRefPubMed

52.

Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007;98(3):268–74. doi:10.1111/j.1349-7006.2007.00389.x.CrossRefPubMed

53.

Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–82. doi:10.1007/s00428-005-1264-9.CrossRefPubMed

54.

Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun. 2013;4:2299. doi:10.1038/ncomms3299.PubMed

55.

Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, et al. Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Sci. 2012;103(2):181–90. doi:10.1111/j.1349-7006.2011.02154.x.CrossRefPubMed

56.

Li L, Zhang J, Xiong N, Li S, Chen Y, Yang H, et al. Notch-1 signaling activates NF-kappaB in human breast carcinoma MDA-MB-231 cells via PP2A-dependent AKT pathway. Med Oncol. 2016;33(4):33. doi:10.1007/s12032-016-0747-7.CrossRefPubMed

57.

Hales EC, Orr SM, Larson Gedman A, Taub JW, Matherly LH. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem. 2013;288(31):22836–48. doi:10.1074/jbc.M113.451625.CrossRefPubMedPubMedCentral

58.

Zhang W, Grivennikov SI. Top Notch cancer stem cells by paracrine NF-kappaB signaling in breast cancer. Breast Cancer Res: BCR. 2013;15(5):316. doi:10.1186/bcr3565.CrossRefPubMedPubMedCentral

59.

Zhao F, Li L, Guan L, Yang H, Wu C, Liu Y. Roles for GP IIb/IIIa and alphavbeta3 integrins in MDA-MB-231 cell invasion and shear flow-induced cancer cell mechanotransduction. Cancer Lett. 2014;344(1):62–73. doi:10.1016/j.canlet.2013.10.019.CrossRefPubMed

60.

Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285(5430):1028–32.CrossRefPubMed

61.

Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697–715. doi:10.1146/annurev.cellbio.12.1.697.CrossRefPubMed

62.

Deford P, Brown K, Richards RL, King A, Newburn K, Westover K, et al. MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis. Exp Cell Res. 2016;341(1):84–91. doi:10.1016/j.yexcr.2016.01.011.CrossRefPubMedPubMedCentral

63.

Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, Haslett C, et al. Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol Chem. 2007;282(39):28991–9001. doi:10.1074/jbc.M703601200.CrossRefPubMed

64.

65.

Kim KH, Chen CC, Alpini G, Lau LF. CCN1 induces hepatic ductular reaction through integrin alphavbeta(5)-mediated activation of NF-kappaB. J Clin Invest. 2015;125(5):1886–900. doi:10.1172/JCI79327.CrossRefPubMedPubMedCentral

66.

Haque I, De A, Majumder M, Mehta S, McGregor D, Banerjee SK, et al. The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis. J Biol Chem. 2012;287(46):38569–79. doi:10.1074/jbc.M112.389064.CrossRefPubMedPubMedCentral

67.

Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol. 2006;7(1):20–31. doi:10.1038/nrm1789.CrossRefPubMed

68.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, et al. Integrin-linked kinase as a novel molecular switch of the IL-6-NF-kappaB signaling loop in breast cancer. Carcinogenesis. 2016;37(4):430–42. doi:10.1093/carcin/bgw020.CrossRefPubMedPubMedCentral

69.

Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging Notch signaling in bone cells. Cancer Cell. 2011;19(2):192–205. doi:10.1016/j.ccr.2010.12.022.CrossRefPubMedPubMedCentral

70.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, et al. Function of integrin-linked kinase in modulating the stemness of IL-6-abundant breast cancer cells by regulating gamma-secretase-mediated Notch1 activation in caveolae. Neoplasia. 2015;17(6):497–508. doi:10.1016/j.neo.2015.06.001.CrossRefPubMedPubMedCentral

71.

Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988–4002. doi:10.1172/JCI32533.CrossRefPubMedPubMedCentral

72.

Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, et al. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 2013;73(6):1900–11. doi:10.1158/0008-5472.CAN-12-3040.CrossRefPubMedPubMedCentral

73.

Lee C, Lee C, Lee S, Siu A, Ramos DM. The cytoplasmic extension of the integrin beta6 subunit regulates epithelial-to-mesenchymal transition. Anticancer Res. 2014;34(2):659–64.PubMed

74.

Ding Y, Shen Y. Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis. Biochem Biophys Res Commun. 2015;467(4):717–22. doi:10.1016/j.bbrc.2015.10.076.CrossRefPubMed

75.

Masia A, Almazan-Moga A, Velasco P, Reventos J, Toran N, Sanchez de Toledo J, et al. Notch-mediated induction of N-cadherin and alpha9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells. Br J Cancer. 2012;107(8):1374–83. doi:10.1038/bjc.2012.411.CrossRefPubMedPubMedCentral

76.

Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610. doi:10.1038/nrg2843.PubMed

77.

Sun DW, Zhang HD, Mao L, Mao CF, Chen W, Cui M, et al. Luteolin inhibits breast cancer development and progression in vitro and in vivo by suppressing Notch signaling and regulating MiRNAs. Cell Physiol Biochem. 2015;37(5):1693–711. doi:10.1159/000438535.CrossRefPubMed

78.

Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 2010;292(2):141–8. doi:10.1016/j.canlet.2009.11.012.CrossRefPubMed

79.

Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 2013;210(8):1545–57. doi:10.1084/jem.20122516.CrossRefPubMedPubMedCentral

80.

Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, Moura-Alves P, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest. 2013;123(11):4836–48. doi:10.1172/JCI67604.CrossRefPubMedPubMedCentral

81.

Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G, Pelullo M, et al. Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. J Immunol. 2011;186(11):6199–206. doi:10.4049/jimmunol.1002136.CrossRefPubMed

82.

Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, Bellavia D, et al. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(12):2324–35. doi:10.1038/leu.2014.133.CrossRefPubMed

83.

Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci: CMLS. 2009;66(5):773–87. doi:10.1007/s00018-008-8465-8.CrossRefPubMed

84.

Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011;30(4):770–82. doi:10.1038/emboj.2010.349.CrossRefPubMedPubMedCentral

85.

Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011;121(4):1373–85. doi:10.1172/JCI42579.CrossRefPubMedPubMedCentral

86.

Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 2011;71(21):6836–47. doi:10.1158/0008-5472.CAN-11-0846.CrossRefPubMedPubMedCentral

87.

Shimono Y, Mukohyama J, Nakamura S, Minami H. MicroRNA regulation of human breast cancer stem cells. J Clin Med. 2015;. doi:10.3390/jcm5010002.PubMedPubMedCentral

88.

Xu YF, Hannafon BN, Ding WQ. microRNA regulation of human pancreatic cancer stem cells. Stem Cell Investig. 2017;4:5. doi:10.21037/sci.2017.01.01.CrossRefPubMedPubMedCentral

89.

Chen J, Zhang H, Chen Y, Qiao G, Jiang W, Ni P, et al. miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell Res. 2017;352(1):104–12. doi:10.1016/j.yexcr.2017.01.022.CrossRefPubMed

90.

Wang XW, Xi XQ, Wu J, Wan YY, Hui HX, Cao XF. MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer. Oncol Rep. 2015;33(3):1402–10. doi:10.3892/or.2015.3731.CrossRefPubMed

91.

Rizzo P, Miao H, D’Souza G, Osipo C, Song LL, Yun J, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008;68(13):5226–35. doi:10.1158/0008-5472.CAN-07-5744.CrossRefPubMedPubMedCentral

92.

Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res: BCR. 2011;13(3):R63. doi:10.1186/bcr2900.CrossRefPubMedPubMedCentral

93.

Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014;4(10):1154–67. doi:10.1158/2159-8290.CD-13-0830.CrossRefPubMedPubMedCentral

94.

Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2012;11(7):1565–75. doi:10.1158/1535-7163.MCT-11-0938.CrossRefPubMedPubMedCentral

95.

Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, et al. Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J Biol Chem. 2017;292(3):837–46. doi:10.1074/jbc.M116.745208.CrossRefPubMed

96.

Notch inhibitor shows modest efficacy. Cancer Discov. 2017;7(2):OF3. doi:10.1158/2159-8290.CD-NB2016-159.

97.

Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, et al. Discovery of clinical candidate BMS-906024: a potent pan-Notch inhibitor for the treatment of leukemia and solid tumors. ACS Med Chem Lett. 2015;6(5):523–7. doi:10.1021/acsmedchemlett.5b00001.CrossRefPubMedPubMedCentral

98.

Knoechel B, Bhatt A, Pan L, Pedamallu CS, Severson E, Gutierrez A, et al. Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the gamma-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud. 2015;1(1):a000539. doi:10.1101/mcs.a000539.CrossRefPubMedPubMedCentral

Title: Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy
Authors: Li Li
Ping Tang
Shun Li
Xiang Qin
Hong Yang
Chunhui Wu
Yiyao Liu
Publication date: 01-10-2017
Publisher: Springer US
Published in: Medical Oncology / Issue 10/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-1039-6

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2017

Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer

Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis

Retraction Note to: Metabolic syndrome factors and risk of postoperative depression in high-grade glioma patients in a 1.5-year prospective study

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer